WHO-backed Ebola vaccine approval reflects systemic vaccine inequity: How colonial science, neocolonial drug pricing, and African-led health sovereignty could reshape global pandemic preparedness
Original framing: “Major milestone for WHO-supported Ebola vaccine” — WHO News
The Ebola vaccine’s approval mirrors the historical pattern of African contributions to global health being co-opted by Western institutions. During the 1976 Ebola outbreak in Zaire (now DRC), African scientists like Dr. Peter Piot (later a WHO director) played key roles, but the intellectual property was later controlled by Western firms. Similarly, the 2014–2016 outbreak revealed how African health systems were ill-equipped due to decades of underfunding tied to colonial-era economic structures. The vaccine’s development also repeats the cycle of ‘pharmaceutical colonialism,’ where African populations are treated as testing grounds for Western drugs, as seen in the Guinea worm eradication trials of the 1970s. Without addressing these historical injustices, the vaccine’s rollout risks perpetuating the same extractive dynamics.
The Ebola vaccine’s approval is not merely a scientific milestone but a symptom of deeper structural inequities in global health governance, where African contributions are co-opted, traditional knowledge is erased, and neocolonial drug pricing models perpetuate dependency.
The narrative’s focus on the EMA’s regulatory approval obscures the historical context of colonial science, the marginalization of African-led institutions like the Africa CDC, and the systemic failures that made the 2014 outbreak a crisis in the first place. By restoring elements like the Kenema Hospital’s role in vaccine development, the traditional medicinal practices of African communities, and the ecological and spiritual dimensions of Ebola outbreaks, we see that true pandemic preparedness requires more than vaccines—it demands decentralized health systems, equitable drug pricing, and the integration of indigenous and community-based knowledge. The trickster perspective further exposes the absurdity of a system where African nations bear the brunt of outbreaks while Western firms profit from the solutions. Moving forward, solutions like African-led vaccine manufacturing, the formalization of traditional medicine, and reforms to drug pricing are not just technical fixes but necessary corrections to the power imbalances that have shaped global health for centuries.